On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy (bamlanivimab) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.
On November 21, 2020, the FDA issued an EUA for the investigational monoclonal antibody therapy (casirivimab and imdevimab) administered together, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Similar to bamlanivimab, casirivimab and imdevimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.
CMS identified specific code(s) for each COVID-19 monoclonal antibody product and specific administration code(s) for Medicare payment:
Q0239:
Long descriptor: Injection, bamlanivimab-xxxx, 700 mg
Short descriptor: bamlanivimab-xxxx
M0239:
Long Descriptor: intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
Short Descriptor: bamlanivimab-xxxx infusion
Q0243:
Long descriptor: Injection, casirivimab and imdevimab, 2400 mg
Short descriptor: casirivimab and imdevimab
M0243:
Long Descriptor: intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
Short Descriptor: casirivi and imdevi infusion
If you purchase product 1, you will be able to get $50 off.
If you purchase products 1 and 2, you will be able to get 100 off.
If you purchase products 1, 2, and 3, you will be able to get $ 150 off.
Click
Take the QUIZ to see how well you know your body: